Pharmaceuticals - Community Register

  

Community register of medicinal products for human use


AUTHORISED  

Product information

Invented name: Menveo   
Auth. number : EU/1/10/614
INN : Meningococcal Group A, C, W135 and Y Conjugate Vaccine
ATC: Anatomical main group: J - General antiinfectives for systemic use
Therapeutic subgroup: J07 - Vaccines
Pharmacological subgroup: J07A - Bacterial vaccines
Chemical subgroup: J07AH - Meningococcal vaccines
Chemical substance: J07AH08 - Meningococcus, tetravalent purified polysaccharides antigen conjugated
(See WHO ATC Index)
Indication: Menveo is indicated for active immunization of children (from 2 years of age), adolescents and adults
at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.
The use of this vaccine should be in accordance with official recommendations.
Marketing Authorisation Holder: Novartis Vaccines and Diagnostics S.r.l.
Via Fiorentina, 1, 53100 Siena, Italia

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
17/03/2010 Centralised - Authorisation EMEA/H/C/1095 (2010)1795 of 15/03/2010
30/04/2010 Centralised - Variation EMEA/H/C/1095/IA/1/G
Updated with Decision(2010)6242 of 06/09/2010
08/07/2010 Centralised - Variation EMEA/H/C/1095/IB/4
Updated with Decision(2010)6242 of 06/09/2010
08/07/2010 Centralised - Variation EMEA/H/C/1095/IA/5
Updated with Decision(2010)6242 of 06/09/2010
19/08/2010 Centralised - Variation EMEA/H/C/1095/II/2
09/09/2010 Centralised - Variation EMEA/H/C/1095/II/3 (2010)6242 of 06/09/2010
04/10/2010 Centralised - Variation EMEA/H/C/1095/N/6
Updated with Decision(2011)556 of 27/01/2011
06/12/2010 Centralised - Variation EMEA/H/C/1095/IB/9
16/12/2010 Centralised - Variation EMEA/H/C/1095/IA/10
Updated with Decision(2011)556 of 27/01/2011
31/01/2011 Centralised - Variation EMEA/H/C/1095/II/7 (2011)556 of 27/01/2011
04/02/2011 Centralised - Variation EMEA/H/C/1095/IA/12
28/02/2011 Centralised - Variation EMEA/H/C/1095/II/8/G
23/03/2011 Centralised - Variation EMEA/H/C/1095/II/11/G (2011)1925 of 18/03/2011
27/04/2011 Centralised - Variation EMEA/H/C/1095/IA/13
Updated with Decision(2011)5524 of 26/07/2011
28/07/2011 Centralised - Variation EMEA/H/C/1095/II/15 (2011)5524 of 26/07/2011
27/04/2012 Centralised - Variation EMEA/H/C/1095/II/17 (2012)2911 of 24/04/2012
29/06/2012 Centralised - Variation EMEA/H/C/1095/II/20 (2012)4488 of 27/06/2012
21/02/2013 Centralised - Variation EMEA/H/C/1095/II/30
Updated with Decision(2014)1466 of 28/02/2014
25/04/2013 Centralised - Variation EMEA/H/C/1095/II/28/G
Updated with Decision(2014)1466 of 28/02/2014
25/04/2013 Centralised - Variation EMEA/H/C/1095/II/18
Updated with Decision(2014)1466 of 28/02/2014
25/10/2013 Centralised - Variation EMEA/H/C/1095/IA/33
Updated with Decision(2014)1466 of 28/02/2014
04/03/2014 Centralised - Variation (2014)1466 of 28/02/2014
25/04/2014 Centralised - Variation EMEA/H/C/1095/II/40
26/06/2014 Centralised - Variation EMEA/H/C/1095/II/38